Despite the majority of prostate cancer patients are diagnosed at a potentially curable stage and treated with radical prostatectomy or other first-line treatments, a subset of patients will experience a recurrence, typically detected by a rise in serum prostate-specific antigen (PSA) levels [2, 3]. This evidence concerns the gene KLK3 and Familial prostate cancer.